Dogwood Therapeutics (NASDAQ:DWTX) Earns “Buy” Rating from HC Wainwright

Dogwood Therapeutics (NASDAQ:DWTX)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 313.79% from the stock’s previous close.

Several other analysts have also recently issued reports on DWTX. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Dogwood Therapeutics currently has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Stock Down 5.5%

NASDAQ:DWTX opened at $2.90 on Friday. The firm has a market capitalization of $6.64 million, a P/E ratio of -0.12 and a beta of 1.90. The company has a fifty day moving average of $4.67 and a 200 day moving average of $5.13. Dogwood Therapeutics has a 52 week low of $2.60 and a 52 week high of $15.00.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($8.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($6.97). As a group, analysts anticipate that Dogwood Therapeutics will post -6.43 EPS for the current year.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical?stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high?throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.